Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) on Friday, plunged -0.81% from the previous trading day, before settling in for the closing price of $27.24. Within the past 52 weeks, BCYC’s price has moved between $12.54 and $28.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 38.55% over the last five years. The company achieved an average annual earnings per share of 37.98%. With a float of $65.84 million, this company’s outstanding shares have now reached $68.94 million.
The firm has a total of 284 workers. Let’s measure their productivity. In terms of profitability, gross margin is 83.2%, operating margin of -522.07%, and the pretax margin is -469.25%.
Bicycle Therapeutics Plc ADR (BCYC) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Bicycle Therapeutics Plc ADR is 4.51%, while institutional ownership is 56.18%. The most recent insider transaction that took place on Jul 03 ’24, was worth 4,831. In this transaction CHIEF PROD & SUPPLY CHAIN OFF of this company sold 246 shares at a rate of $19.64, taking the stock ownership to the 22,645 shares. Before that another transaction happened on Jul 03 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 967 for $19.64, making the entire transaction worth $18,992. This insider now owns 93,917 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 37.98% per share during the next fiscal year.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
Bicycle Therapeutics Plc ADR (BCYC) is currently performing well based on its current performance indicators. A quick ratio of 14.77 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.81, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -3.56 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Analysing the last 5-days average volume posted by the [Bicycle Therapeutics Plc ADR, BCYC], we can find that recorded value of 0.64 million was better than the volume posted last year of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 87.60%. Additionally, its Average True Range was 1.59.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 86.79%, which indicates a significant increase from 85.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.82% in the past 14 days, which was higher than the 60.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.04, while its 200-day Moving Average is $21.54. Now, the first resistance to watch is $27.97. This is followed by the second major resistance level at $28.92. The third major resistance level sits at $30.22. If the price goes on to break the first support level at $25.72, it is likely to go to the next support level at $24.42. Now, if the price goes above the second support level, the third support stands at $23.47.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
Market capitalization of the company is 1.86 billion based on 42,779K outstanding shares. Right now, sales total 26,980 K and income totals -180,660 K. The company made 9,360 K in profit during its latest quarter, and -39,810 K in sales during its previous quarter.
